Jessy Delaye

667 total citations · 1 hit paper
9 papers, 384 citations indexed

About

Jessy Delaye is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jessy Delaye has authored 9 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Otorhinolaryngology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jessy Delaye's work include Sarcoma Diagnosis and Treatment (4 papers), Head and Neck Cancer Studies (4 papers) and Colorectal and Anal Carcinomas (2 papers). Jessy Delaye is often cited by papers focused on Sarcoma Diagnosis and Treatment (4 papers), Head and Neck Cancer Studies (4 papers) and Colorectal and Anal Carcinomas (2 papers). Jessy Delaye collaborates with scholars based in France, Switzerland and Guadeloupe. Jessy Delaye's co-authors include Sophie Piperno‐Neumann, Sylvie Chabaud, Emmanuelle Bompas, Olivier Collard, Florence Duffaud, Antoîne Italiano, Jean‐Yves Blay, Nicolas Penel, Christine Chevreau and Pascaline Boudou‐Rouquette and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Cancer.

In The Last Decade

Jessy Delaye

9 papers receiving 382 citations

Hit Papers

Efficacy and safety of regorafenib in adult patients with... 2018 2026 2020 2023 2018 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
    2018 229 citations Florence Duffaud, Olivier Mir et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jessy Delaye France 6 215 199 112 76 67 9 384
Seiko Sawada‐Kitamura Japan 13 105 0.5× 107 0.5× 97 0.9× 109 1.4× 42 0.6× 16 375
Aylin Örgen Çallı Türkiye 12 118 0.5× 101 0.5× 110 1.0× 74 1.0× 26 0.4× 48 341
Seog-Yun Park South Korea 10 172 0.8× 170 0.9× 72 0.6× 138 1.8× 75 1.1× 22 433
Kanae Nosaka Japan 12 135 0.6× 153 0.8× 59 0.5× 178 2.3× 98 1.5× 36 425
Camille Schiffler France 10 251 1.2× 152 0.8× 49 0.4× 87 1.1× 67 1.0× 24 385
Riikka Huuhtanen Finland 14 312 1.5× 249 1.3× 129 1.2× 100 1.3× 61 0.9× 21 487
Seiichi Fukuyama Japan 12 186 0.9× 190 1.0× 70 0.6× 76 1.0× 65 1.0× 26 422
Patricia C. Ewing‐Graham Netherlands 13 74 0.3× 137 0.7× 192 1.7× 122 1.6× 86 1.3× 39 528
Jinchen Shao China 14 358 1.7× 233 1.2× 259 2.3× 82 1.1× 71 1.1× 40 550
Rosa Rinaldi Italy 13 110 0.5× 179 0.9× 71 0.6× 116 1.5× 143 2.1× 36 421

Countries citing papers authored by Jessy Delaye

Since Specialization
Citations

This map shows the geographic impact of Jessy Delaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessy Delaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessy Delaye more than expected).

Fields of papers citing papers by Jessy Delaye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessy Delaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessy Delaye. The network helps show where Jessy Delaye may publish in the future.

Co-authorship network of co-authors of Jessy Delaye

This figure shows the co-authorship network connecting the top 25 collaborators of Jessy Delaye. A scholar is included among the top collaborators of Jessy Delaye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessy Delaye. Jessy Delaye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Piperno‐Neumann, Sophie, Isabelle Ray‐Coquard, Bob‐Valéry Occéan, et al.. (2019). Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study. International Journal of Cancer. 146(2). 413–423. 27 indexed citations
2.
Piperno‐Neumann, Sophie, Jessy Delaye, Laurence Brugières, et al.. (2019). Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. BMJ Open. 9(5). e025877–e025877. 23 indexed citations
3.
Mirghani, H., Carine Bellera, Jessy Delaye, et al.. (2019). Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Cancer Epidemiology. 61. 89–94. 26 indexed citations
4.
5.
6.
Duffaud, Florence, Olivier Mir, Pascaline Boudou‐Rouquette, et al.. (2018). Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Oncology. 20(1). 120–133. 229 indexed citations breakdown →
7.
8.
Guigay, J., Jérôme Fayette, Caroline Even, et al.. (2016). PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).. Journal of Clinical Oncology. 34(15_suppl). 6086–6086. 22 indexed citations
9.
Abadie‐Lacourtoisie, Sophie, P Soulié, P. Maillart, et al.. (2014). Oral chemotherapy or targeted therapy compliance: An observational multicenter French study in cancer patients.. Journal of Clinical Oncology. 32(15_suppl). e11562–e11562. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seiko Sawada‐Kitamura Breakdown of academic impact, for papers by Aylin Örgen Çallı Breakdown of academic impact, for papers by Seog-Yun Park Breakdown of academic impact, for papers by Kanae Nosaka Breakdown of academic impact, for papers by Camille Schiffler Breakdown of academic impact, for papers by Riikka Huuhtanen Breakdown of academic impact, for papers by Seiichi Fukuyama Breakdown of academic impact, for papers by Patricia C. Ewing‐Graham Breakdown of academic impact, for papers by Jinchen Shao Breakdown of academic impact, for papers by Rosa Rinaldi
Rankless by CCL
2026